Key result
Phosphoramidon and EDTA inhibit human brain metalloprotease from converting big ET-1 to ET-1.
The human brain contains a metalloprotease that selectively converts big endothelin-1 to endothelin-1, suggesting the presence of a complete synthetic pathway for ET-1 in the brain.
Answers are grounded in this paper and cite their sources.
Supports local ET-1 synthesis in human brain; leaves open its role in cerebrovascular disease pending in vivo confirmation.
Incubation of big endothelin-1 (bET-1) with protein derived from the detergent-extracted 100,000 g pellet prepared from human brain tissue resulted in the formation of endothelin-1 (ET-1) at a rate of 90 fmol mg-1 protein min-1. This formation was inhibited in a concentration-dependent manner by either phosphoramidon or EDTA, with half-maximal inhibitory concentrations of 2 and 20 microM, respectively. No conversion of big endothelin-3 (bET-3) to endothelin-3 (ET-3) was detected under the same conditions. These results show the presence in the human brain of a metalloprotease-like enzymatic activity which selectively converts bET-1 and ET-1. Together with earlier reports of mRNA for ET-1 this suggests the presence of the entire synthetic pathway for ET-1 in human brain.
No takes yet. Share an insight, caveat, or question.
Warner et al. (1992) studied this question. phosphoramidon and EDTA was evaluated on formation of endothelin-1 (ET-1). A metalloprotease in human brain tissue selectively converted big endothelin-1 to endothelin-1 at a rate of 90 fmol/mg/min, which was inhibited by phosphoramidon (IC50 2 µM) and EDTA (IC50 20 µM).
Synapse has enriched 10 related papers. Consider them for comparative context: